Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration
Synapse · 2017-10 · 71 (10) · e21990
DOI: 10.1002/syn.21990 ↗At a glance
Übersichtsarbeit in Synapse, published online on 2017-08-02. Written by Eduardo Rojas-Gutierrez and 8 co-authors. Institution: Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico. Cited 189 times so far (Crossref); 312 references. Funded by: VIEP-BUAP, PAPIT-UNAM, Benemérita Universidad Autónoma de Puebla.
Topics: Demenz
Abstract (original language)
Alzheimer's disease (AD) is the most common cause of dementia and one of the most important causes of morbidity and mortality among the aging population. AD diagnosis is made post-mortem, and the two pathologic hallmarks, particularly evident in the end stages of the illness, are amyloid plaques and neurofibrillary tangles. Currently, there is no curative treatment for AD. Additionally, there is a strong relation between oxidative stress, metabolic syndrome, and AD. The high levels of circulating lipids and glucose imbalances amplify lipid peroxidation that gradually diminishes the antioxidant systems, causing high levels of oxidative metabolism that affects cell structure, leading to neuronal damage. Accumulating evidence suggests that AD is closely related to a dysfunction of both insulin signaling and glucose metabolism in the brain, leading to an insulin-resistant brain state. Four drugs are currently used for this pathology: Three FDA-approved cholinesterase inhibitors and one NMDA receptor antagonist. However, wide varieties of antioxidants are promissory to delay or prevent the symptoms of AD and may help in treating the disease. Therefore, therapeutic efforts to achieve attenuation of oxidative stress could be beneficial in AD treatment, attenuating Aβ-induced neurotoxicity and improve neurological outcomes in AD. The term inflammaging characterizes a widely accepted paradigm that aging is accompanied by a low-grade chronic up-regulation of certain pro-inflammatory responses in the absence of overt infection, and is a highly significant risk factor for both morbidity and mortality in the elderly.
Subjects
Author keywords
Authors and institutions
- Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
- Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Pue, Mexico.
- Departamento de Bioquímica, Instituto Nacional de Enfermedades Respiratorias-INER, Ciudad de México, Mexico.
- Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla, Puebla, Pue, Mexico.
Funding
- VIEP-BUAP
- PAPIT-UNAM
- Benemérita Universidad Autónoma de Puebla
- Universidad Nacional Autónoma de México
Cite
APA
Rojas-Gutierrez, E., Muñoz-Arenas, G., Treviño, S., Espinosa, B., Chavez, R., Rojas, K., Flores, G., Díaz, A., & Guevara, J. (2017). Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. Synapse, 71(10), e21990. https://doi.org/10.1002/syn.21990
Vancouver
Rojas-Gutierrez E, Muñoz-Arenas G, Treviño S, Espinosa B, Chavez R, Rojas K, et al. Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. Synapse. 2017;71(10):e21990. doi:10.1002/syn.21990
BibTeX
@article{RojasGutierrez2017,
author = {Rojas-Gutierrez, Eduardo and Muñoz-Arenas, Guadalupe and Treviño, Samuel and Espinosa, Blanca and Chavez, Raúl and Rojas, Karla and Flores, Gonzalo and Díaz, Alfonso and Guevara, Jorge},
title = {Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration},
journal = {Synapse},
year = {2017},
volume = {71},
number = {10},
pages = {e21990},
doi = {10.1002/syn.21990}
}
EUVIMED